| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | 144 |
| 06 Nov 2026 |
Form 4: Sakhamuri Sivakesava, Chief Technical Officer
Granted 90,000 Stock Option (Right to Buy) · Granted 40,000 Restricted Stock Units |
| 02 Nov 2026 |
Form 3: Sakhamuri Sivakesava, Chief Technical Officer
No securities owned |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – |
| 28 Oct 2026 |
Form 4: Silver Andrew Jacob, Chief Financial Officer
Granted 18,000 Stock Option (Right to Buy) · Granted 9,000 Restricted Stock Units |
| 28 Oct 2026 |
Form 4: Kasinger James R., General Counsel and Secretary
Granted 18,000 Stock Option (Right to Buy) · Granted 9,000 Restricted Stock Units |
| 28 Oct 2026 |
Form 4: Kulkarni Samarth, Director
Granted 57,500 Stock Option (Right to Buy) · Granted 28,750 Restricted Stock Units |
| 28 Oct 2026 |
Form 4: Patel Naimish, Chief Medical Officer
Granted 24,000 Stock Option (Right to Buy) · Granted 12,000 Restricted Stock Units |
| 21 Oct 2026 |
Form 4: Silver Andrew Jacob, Chief Financial Officer
Granted 25,000 Restricted Stock Units |
| 21 Oct 2026 | Form 3: Silver Andrew Jacob, Chief Financial Officer |
| 20 Oct 2026 |
Form 4: Kulkarni Samarth, Director
Received 100,000 shares by exercise or conversion · Sold 47,837 shares ($2.38M) |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (“Agreement”) is made as of the Nineteenth (19th) day of October, 2026 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew J. Silver (the “Executive” and, together with the Comp... |
| 16 Oct 2026 |
Form 4: George Simeon, Director
Received 30,000 shares by exercise or conversion ($420K) · Sold 14,514 shares ($720K) |
| 15 Oct 2026 |
Form 4: Kasinger James R., General Counsel and Secretary
Received 2,113 shares by exercise or conversion · Sold 1,040 shares ($51.2K) |
| 15 Oct 2026 |
Form 4: Kulkarni Samarth, Director
Received 8,333 shares by exercise or conversion · Sold 4,098 shares ($202K) |
| 14 Oct 2026 | 144 |
Loading...